← Human Trials & Peer-Reviewed Studies
Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide
Plain-language guide to PMID 12495560 (2002): placebo-controlled clinical trial study of VIP (Vasoactive Intestinal Peptide) and CGRP (Calcitonin Gene-Related Peptide).
Key Facts
- PMID
- 12495560
- Journal
- The Journal of pharmacy and pharmacology
- Year
- 2002
- Study type
- Clinical Trial
- Authors
- Itoh H et al. (3 authors)
- DOI
- 10.1211/002235702117
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of VIP (Vasoactive Intestinal Peptide) and CGRP (Calcitonin Gene-Related Peptide), published as a clinical trial.
The effects of the histamine H(2)-receptor antagonists (H(2)-antagonists), ranitidine, nizatidine, cimetidine and famotidine, on plasma levels of gastrointestinal peptides, calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal peptide (VIP) was investigated with respect to regulation of gastric mucosal blood flow, in healthy volunteers.
H(2)-Antagonists or placebo was orally administered to five healthy male volunteers.
Who Took Part
PubMed indexes the participants as adults, men only.
How the Study Was Run
The researchers set it up as a placebo-controlled study.
A placebo (an inactive look-alike) gave the VIP (Vasoactive Intestinal Peptide) group a baseline to be compared against.
What Was Measured
The effects of the histamine H(2)-receptor antagonists (H(2)-antagonists), ranitidine, nizatidine, cimetidine and famotidine, on plasma levels of gastrointestinal peptides, calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal peptide (VIP) was investigated with respect to regulation of gastric mucosal blood flow, in healthy volunteers.
The levels of plasma gastrointestinal peptides were determined by enzyme immunoassay.
The subject headings attached to it are Calcitonin Gene-Related Peptide, Cimetidine, Famotidine, Histamine H2 Antagonists, Nizatidine, Ranitidine and Substance P.
What This Means in Plain Language
The paper is a placebo-controlled study of VIP (Vasoactive Intestinal Peptide) and CGRP (Calcitonin Gene-Related Peptide).
The publication is from 2002 (The Journal of pharmacy and pharmacology), a journal based in England.
More context: the VIP (Vasoactive Intestinal Peptide) compound page and the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.
Our Notes on the Compounds
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Substance P: An 11-amino-acid neuropeptide involved in pain signaling and inflammation; given in research studies.
Related Pages
- VIP (Vasoactive Intestinal Peptide) in the library
- CGRP (Calcitonin Gene-Related Peptide) in the library
- Substance P in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.